Palisade Bio vs Scholar Rock
PALI and SRRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PALI and SRRK compare
Scholar Rock is the larger company, worth 31 times as much as Palisade Bio ($5.5B against $176M).
Palisade Bio scores higher on the StockData Score (7 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PALI | SRRK |
|---|---|---|
| Size and price | ||
| Market cap | $176M | $5.5B |
| Share price | $1.01 | $45.08 |
| Change, 1 year | −52.8% | 20.5% |
| Change, 5 years | −99.9% | 67.1% |
| Beta (5Y) | 1.15 | 0.83 |
| Employees | 100K | 289 |
| StockData Score | ||
| Total score | 7 (better) | 2 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 352× | – |
| P/B | 1.4× (better) | 21.6× |
| FCF yield | – | −5.4% |
| Profitability | ||
| Operating margin | −7070% | – |
| Net margin | −6388% | – |
| Return on equity | −51.4% (better) | −168% |
| Financial health | ||
| Debt / equity | 0.00 | 0.77 (better) |
| Interest coverage | −4418.6× | −38.0× (better) |
| Current ratio | 24.26 (better) | 7.02 |
| Altman Z-score | 19.21 (better) | 6.59 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | −74.7% | −4.6% (better) |
| Shareholder yield | −74.7% | −4.6% (better) |
| Ownership | ||
| Held by institutions | 99.5% | 114% |
| Held by insiders | 4.7% | 28.9% |
| Insider net buying, 12 months | −$124K (better) | −$7.4M |
| Short interest, % of float | 17.6% | 27.1% |
Go deeper
- PALI stock overview
- PALI income statement
- PALI valuation and score
- SRRK stock overview
- SRRK income statement
- SRRK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.